Related Experiment Video
Updated: Mar 18, 2026
Personalized Peptide Arrays for Detection of HLA Alloantibodies in Organ Transplantation
Published on: September 6, 2017
Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA-Peptide Multimer Staining Assay
P Anoop Chandran1, Karoline Laske1, Angelica Cazaly2
1Department of Immunology, Institute for Cell Biology, Eberhard Karls University, and German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) Partner Site Tuebingen, Tuebingen, Germany.
Insights
We systematically validated the HLA-peptide multimer staining assay for reliable monitoring of T cell responses. This assay meets key performance criteria, ensuring data quality for immunotherapy research.
Area of Science:
- Immunology
- Cellular Assays
- Clinical Research
Background:
- Validated assays are crucial for reliable data in clinical studies.
- Systematic validation of in vitro T cell assays is infrequently reported.
- Immunoassays require validation for clinical study application.
Purpose of the Study:
- To systematically validate the HLA-peptide multimer staining assay.
- To qualify the assay for monitoring antigen-specific T cell responses post-immunotherapy.
- To provide a framework for validating other T cell assessment methods.
Main Methods:
- Systematic assessment of assay parameters including specificity, precision, linearity, sensitivity, and robustness.
- Designed experiments to specifically address each validation parameter.
- Utilized HLA-peptide multimer staining technique.
Main Results:
- Nonspecific multimer staining was below the 0.02% acceptance limit.
- Assay demonstrated acceptable precision (CV < 10%) across all dimensions.
- Linear detection of antigen-specific cells was achieved (R² > 0.99).
Conclusions:
- Successful systematic validation of the HLA-multimer staining assay was achieved.
- The study proposes a technical framework and recommendations for validating T cell assays.
- The validated assay is suitable for monitoring T cell responses in immunotherapy contexts.
Background:
Validated assays are essential to generate data with defined specificity, consistency, and reliability. Although the process of validation is required for applying immunoassays in the context of clinical studies, reports on systematic validation of in vitro T cell assays are scarce so far. We recently validated our HLA-peptide multimer staining assay in a systematic manner so as to qualify the method for monitoring antigen-specific T cell responses after immunotherapy.
Methods:
Parameters of the assay, specificity, precision, linearity, sensitivity, and robustness were assessed systematically. Experiments were designed to address specifically each parameter and are detailed.
Results:
Nonspecific multimer staining was below the acceptance limit of 0.02% multimer(+) CD8(+) cells. The assay showed acceptable precision in all dimensions it was repeated (CV < 10%) and also demonstrated a linear detection (R2 > 0.99) of antigen specific cells.
Conclusions:
We succeeded in validating the HLA-multimer staining assay in a systematic manner. Additionally, we propose a technical framework and recommendations that can be applied for validating other T cell assessment methods. © 2016 International Clinical Cytometry Society.
